Clinical Trial

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Study acronym: SHIELD
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-26; most recent amendment 2025-12-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-18
Trial Details
NCT Number NCT06958796
Lead Sponsor Camille N. Kotton, MD
Collaborators: University of Texas Southwestern Medical Center, Kamada, Ltd.
Conditions Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Enrollment 80 participants
Start Date 2025-11-27
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-22